The European Medicines Agency has given positive opinions for four medicines, one of which is AstraZeneca’s Iressa (gefitinib), a targeted treatment for non-small cell lung cancer. The positive opinion follows an earlier application withdrawal. ---Subscribe to MedNous to access this article--- Regulation & Policy
